Estrogen, Signal Transduction, and Systemic Lupus Erythematosus: Molecular Mechanisms

Principles of Gender-Specific Medicine

Volumn 2, Issue , 2004, Pages 1082-1092

  Kammer, Gary M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79953292166     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012440905-7/50375-3     Document Type: Chapter

References (154)

1. Kammer GM, Tsokos GC Lupus: Molecular and Cellular Pathogenesis 1999, Humana Press, Totowa, NJ.
2. Harvey AM, Shulman LE, Tumulty PA Systemic lupus erythematosus: review of the literature and clinical analysis of 138 cases. Medicine 1954, 33:291-437.
3. Hochberg MC Epidemiology of systemic lupus erythematosus. Systemic Lupus Erythematosus 1992, 103-117. Churchill Livingstone, New York. R.G. Lahita (Ed.).
4. Lahita RG The connective tissue diseases and the overall influence of gender. Int J Fertil Menopausal Stud. 1996, 41:156-165.
5. Lahita RG The importance of estrogens in systemic lupus erythematosus. Clin Immunol Immunopathol 1992, 63:17-18.
6. McMurray RW Sex hormones in the pathogenesis of systemic lupus erythematosus. Frontiers Biosci 2001, 6:193-206.
7. Watson CS, Gametchu B Membrane estrogen and glucocorticoid receptors-implications for hormonal control of immune function and autoimmunity. Int Immunopharmacol 2001, 1:1049-1063.
8. Okasha SA, Ryu S, Do Y, et al. Evidence for estradiol-induced apoptosis and dysregulated T cell maturation in the thymus. Toxicology 2001, 163:49-62.
9. Jenkins JK, Suwannaroj S, Elbourne KB, et al. 17-β-Estradiol alters Jurkat lymphocyte cell cycling and induces apoptosis through suppression of Bcl-2 and cyclin A. Int Immunopharmacol 2001, 1:1897-1911.
10. Rider V, Abdou NI Gender differences in autoimmunity: molecular basis for estrogen effects in systemic lupus erythematosus. Int Immunopharmacol 2001, 1:1009-1024.
11. Bynoe MS, Grimaldi CM, Diamond B Estrogen up-regulates Bcl-2 and blocks tolerance induction of naïve B cells. Proc Natl Acad Sci USA 2000, 97:2703-2708.
12. Tsokos GC Overview of cellular immune function in systemic lupus erythematosus. Systemic Lupus Erythematosus 1999, 17-54. Academic Press, New York. R.G. Lahita (Ed.).
13. Dayal AK, Kammer GM The T cell enigma in lupus. Arthritis Rheum. 1996, 39:23-33.
14. Tsokos GC, Kammer GM Molecular aberrations in human systemic lupus erythematosus. Mol Med Today 2000, 6:418-424.
15. Casciola-Rosen LA, Anhalt G, Rosen A Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med. 1994, 179:1317-1330.
16. Kammer GM, Perl A, Richardson BC, et al. Abnormal T cell signal transduction in systemic lupus erythematosus. Arthritis Rheum. 2002, 46:1139-1154.
17. + cells. Hum Immunol. 1986, 17:456-470.
18. Koshy M, Berger D, Crow MK Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996, 98:826-837.
19. Utermohlen V, Winfield JB, Zabriskie JB, et al. A depression of cell-mediated immunity to measles antigen in patients with systemic lupus etythematosus. J Exp Med. 1974, 139:1019-1024.
20. Richardson BC, Strahler JR, Pivirotto TS, et al. Phenotypic and functional similarities between 5-azacytidine-treated T cells and a T cell subset in patients with active systemic lupus erythematosus. Arthritis Rheum. 1992, 35:647-662.
21. Richardson BC, Powers D, Hooper F, et al. Lymphocyte function-associated antigen 1 overexpression and T cell autoreactivity. Arthritis Rheum. 1994, 37:1363-1372.
22. Inghirami G, Simon J, Balow JE, et al. Activated T lymphocytes in the peripheral blood of patients with systemic lupus erythematosus induce B cells to produce immunoglobulin. Clin Exp Rheumatol. 1988, 6:269-276.
23. Kammer GM High prevalence of T cell type I protein kinase A deficiency in systemic lupus erythematosus. Arthritis Rheum. 1999, 42:1458-1465.
24. Froncek MJ, Horwitz DA Cytokines in the pathogenesis of systemic lupus erythematosus. Dubois' Lupus Erythematosus 2002, 187-204. Lippincott Williams & Wilkins, Philadelphia. D.J. Wallace, B.H. Hahn (Eds.).
25. Kaneko H, Ogasawara H, Naito T, et al. Circulating levels of β-chemokines in systemic lupus erythematosus. J Rheumatol. 1999, 26:568-573.
26. Desai-Mehta A, Lu LJ, Ramsey-Goldmarr R, et al. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest. 1996, 97:2063-2073.
27. Wener MH Immune complexes. Principles of Molecular Rheumatology 2000, 127-144. Human Press, Totowa, NJ. G.C. Tsokos (Ed.).
28. Hahn BH Antibodies to DNA. N Engl J Med. 1998, 338:1359-1368.
29. Kammer GM, Stein RL T lymphocyte immune dysfunctions in systemic lupus erythematosus. J Lab Clin Med. 1990, 115:273-282.
30. Mandler R, Birch RE, Polmar S, et al. Abnormal adenosine-induced immunosuppression and caMP metabolism in T lymphocytes of patients with systemic lupus erythematosus. Proc Natl Acad Sci USA 1982, 79:7542-7546.
31. Liossis SNC, Ding XZ, Dennis GJ, et al. Altered pattern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus-Deficient expression of the T cell receptor zeta chain. J Clin Invest. 1998, 101:1448-1457.
32. Takeuchi T, Tsuzaka K, Pang M, et al. TCRβ chain lacking exon 7 in two patients with systemic lupus erythematosus. Int Immunol. 1998, 10:911-921.
33. Brundula V, Rivas LJ, Blasini AM, et al. Diminished levels of T cell receptor zeta chains in peripheral blood T lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum. 1999, 42:1908-1916.
34. Laxminarayana D, Khan IU, Mishra N, et al. Diminished levels of protein kinase A RIα and RIβ transcripts and proteins in systemic lupus erythematosus T lymphocytes. J Immunol. 1999, 162:5639-5648.
35. Grolleau A, Kaplan MJ, Hanash SM, et al. Impaired translational response and increased protein kinase PKR expression in T cells from lupus patients. J Clin Invest. 2000, 106:1561-1568.
36. Vassilopoulos D, Kovacs B, Tsokos GC TCR/CD3 complex-mediated signal transduction pathway in T cells and T cell lines from patients with systemic lupus erythematosus. J Immunol. 1995, 155:2269-2281.
37. Gergely P, Grossman C, Niland B, et al. Mitochondrial hyper-polarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum. 2002, 46:175-190.
38. Deng C, Kaplan MJ, Yang J, et al. Decreased ras-mitogen-activated protein kinase signaling may cause DNA hypomethylation in T lymphocytes from lupus patients. Arthritis Rheum 2001, 44:397-407.
39. Jensen EV, Jacobson HI Basic guides to the mechanism of estrogen action. Recent Prog Horm Res. 1962, 18:387-414.
40. Walter P, Green S, Greene G, et al. Cloning of the human estrogen receptor cDNA. Proc Natl Acad Sci USA 1985, 82:7889-7893.
41. Green S, Walter P, Kumar V, et al. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 1986, 320:134-139.
42. Greene GL, Gilna P, Waterfield M, et al. Sequence and expression of human estrogen receptor complementary DNA. Science. 1986, 231:1150-1154.
43. Kuiper GGJM, Enmark E, Pelto-Huikko M, et al. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996, 93:5925-5930.
44. Gustafsson JA Estrogen receptor β-a new dimension in estrogen mechanism of action. J Endocrinol. 1999, 163:379-383.
45. Mosselman S, Polman J, Dijkema R ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996, 392:49-53.
46. Suenaga R, Evans MJ, Mitamura K, et al. Peripheral blood T cells and monocytes and B cell lines derived from patients with lupus express estrogen receptor transcripts similar to those of normal cells. J Rheumatol. 1998, 25:1305-1312.
47. Kassi EN, Vlachoyiannopoulos PG, Moutsopoulos HM, et al. Molecular analysis of estrogen receptor alpha and beta in lupus patients. Eur J Clin Invest. 2001, 31:86-93.
48. Cohen JHM, Danel L, Cordier G, et al. Sex steroid receptors in peripheral T cells: absence of androgen receptors and restriction of estrogen receptors to OKT8-positive cells. J Immunol. 1983, 131:2767-2771.
49. Stimson WH Oestrogen and human T lymphocytes: Presence of specific receptors in the T-suppressor/cytotoxic subset. Scand J Immunol. 1988, 28:345-350.
50. Tornwall J, Carey AB, Fox RI, et al. Estrogen in autoimmunity: expression of estrogen receptors in thymic and autoimmune T cells. J Gend Specif Med. 1999, 2:33-40.
51. Mor G, Munoz A, Redlinger R, et al. The role of the Fas/Fas ligand system in estrogen-induced thymic alteration. Am J Reprod Immunol. 2001, 46:298-307.
52. Suenaga R, Rider V, Evans MJ, et al. In vitro-activated human lupus T cells express normal estrogen receptor proteins which bind to the estrogen response element. Lupus. 2001, 10:116-122.
53. Ogawa S, Inoue S, Watanabe T, et al. The complete primary structure of human estrogen receptor beta (hERbeta) and its heterodimerization with ER alpha in vivo and in vitro. Biochem Biophys Res Commun. 1998, 243:122-126.
54. Moore JT, McKee DD, Slentz-Kesler K, et al. Cloning and characterization of humna estrogen receptor beta isoforms. Biochem Biophys Res Commun. 1998, 247:75-78.
55. Bhat RA, Harnish DC, Stevis PE, et al. A novel human estrogen receptor beta: identification and functional analysis of additional N-terminal amino acids. J Steroid Biochem Mol Biol. 1998, 67:233-240.
56. Maruyama K, Endoh H, Sasaki-Iwaoka H, et al. A novel isoform of rat estrogen receptor beta with 18 amino acid insertion in the ligand binding domain as a putative dominant negative regulation of estrogen action. Biochem Biophys Res Commun. 1998, 246:142-147.
57. Petersen DN, Tkalcevic GT, Koza-Taylor PH, et al. Identification of estrogen receptor beta2, a functional variant of estrogen receptor beta expressed in normal rat tissues. Endocrinology. 1998, 139:1082-1092.
58. Parker MG Structure and function of estrogen receptors. Vitam Horm. 1995, 51:267-287.
59. Enmark E, Gustafsson JA Oestrogen receptors-an overview. J Int Med. 1999, 246:133-138.
60. Nagpal S, Friant S, Nakshatri H, et al. RARs and RXRs: evidence for two autonomous transactivation functions (AF-1 and AF-2) and heterodimerization in vivo. EMBO J. 1993, 12:2349-2360.
61. Martinez E, Wahli W Cooperative binding of estrogen receptor in imperfect estrogen-responsive DNA elements correlates with their synergistic hormone-dependent enhancer activity. EMBO J. 1989, 8:3781-3791.
62. Tremblay GB, Tremblay A, Labrie F, et al. Dominant activity of activation function 1 (AF-1) and differential stoichiometric requirements for AF-1 and -2 in the estrogen receptor alpha-beta heterodimeric complex. Mol Cell Biol. 1999, 19:1919-1927.
63. Ogawa S, Inoue S, Orimo A, et al. Cross-inhibition of both estrogen receptor alpha and beta pathways by each dominant-negative mutant. FEBS Lett. 1998, 423:129-132.
64. Kato S, Tora L, Yamauchi J, et al. A far upstream estrogen response element of the ovalbumin gene contains several half-palindromic 5'-TGACC-3' motifs acting synergistically. Cell. 1992, 68:731-742.
65. Hyder SM, Chiappetta C, Stancel GM Interaction of human estrogen receptors α and β with the same naturally occurring estrogen response elements. Biochem Pharmacol. 1999, 57:597-601.
66. Tremblay GB, Tremblay A, Copeland NG, et al. Cloning, chromosomal localization, and functional analysis of the murne estrogen receptor beta. Mol Endocrinol. 1997, 11:353-365.
67. Tora L, White J, Brou C, et al. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell. 1989, 59:477-487.
68. Kobayashi Y, Kitamoto T, Masuhiro Y, et al. p300 mediates functional synergism between AF-1 and AF-2 of estrogen receptor α and β by interacting directly with the N-terminal A/B domains. J Biol Chem. 2000, 275:15645-15651.
69. Schwabe JW, Neuhaus D, Rhodes D Solution structure of the DNA-binding domain of the oestrogen receptor. Nature. 1990, 348:458-461.
70. Schwabe JW, Chapman L, Finch JT, et al. The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: how receptors discriminate between their response elements. Cell. 1993, 75:567-578.
71. Kuntz MA, Shapiro DJ Dimerizing the estrogen receptor DNA binding domain enhances binding to estrogen response elements. J Biol Chem. 1997, 272:27949-27956.
72. Glass CK Differential recognition of target genes by nuclear receptor monomers, dimers, and heterodimers. Endocr Rev. 1994, 15:391-407.
73. Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997, 389:753-758.
74. Shiau AK, Barstad D, Loria PM, et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 1998, 95:927-937.
75. Wurtz JM, Bourguet W, Renaud JP, et al. A canonical structure for the ligand-binding domain of nuclear receptors. Nat Struc Biol. 1996, 3:206.
76. Heery M, Kalkhoven E, Hoare S, et al. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature. 1997, 387:733-736.
77. Watanabe T, Inoue S, Ogawa S, et al. Agonistic effect of tamoxifen is dependent on the cell type, ERE-promoter context and estrogen subtype: Functional difference between estrogen receptors α and β. Biochem Biophys Res Commun. 1997, 236:140-145.
78. Barkhem T, Carlsson B, Nilsson Y, et al. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol Pharmacol. 1998, 54:105-112.
79. Kelly MJ, Levin ER Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol Metab. 2001, 12:152-156.
80. Stefano GB, Prevot V, Beauvillain JC, et al. Estradiol coupling to human monocyte nitric oxide release is dependent on intracellular calcium transients: evidence for an estrogen surface receptor. J Immunol. 1999, 163:3758-3763.
81. Razandi M, Pedram A, Levin ER Estrogen signals to the preservation of endothelial cell form and function. J Biol Chem 2000, 275:38540-38546.
82. Chen Z, Yuhanna IS, Galcheva-Gargova Z, et al. Estrogen receptor α mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 1999, 103:401-406.
83. Benten WP, Lieberherr M, Giese G, et al. Estradiol binding to cell surface raises cytosolic free calcium in T cells. FEBS Lett 1998, 422:349-353.
84. Norfleet AM, Thomas ML, Gametchu B, et al. Estrogen receptor-alpha detected on the plasma membrane of aldehyde-fixed GH3/B6/F10 rat pituitary tumor cells by enzyme linked immunocytochemistry. Endocrinology 1999, 140:3805-3814.
85. Norfleet AM, Clarke CH, Gametchu B, et al. Antibodies to the estrogen receptor-alpha modulate rapid prolactin release from rat pituitary tumor cells through plasma membrane estrogen receptors. FASEB J 2000, 14:157-165.
86. Lagrange AH, Ronnekleiv OK, Kelly MJ Modulation of G proteincoupled receptors by an estrogen receptor that activates protein kinase A. Mol Pharmacol 1997, 51:605-612.
87. Razandi M, Pedram A, Greene GL, et al. Cell membrane and nuclear estrogen receptors derive from a single transcript: studies of ERα and ERβ expressed in CHO cells. Mol Endocrinol 1999, 13:307-319.
88. Le Mellay V, Grosse B, Lieberherr M Phospholipase C beta and membrane action of calcitriol and estradiol. J Biol Chem 1997, 272:11902-11907.
89. 2+ influxes. Biochem J 1999, 339:71-77.
90. 2+] by 17β-oestradiol in rat distal colon. Br J Pharmacol 2000, 129:1375-1386.
91. McKenna NJ, O'Malley BW Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 2002, 108:465-474.
92. Hermanson O, Glass CK, Rosenfeld MG Nuclear receptor coregulators: multiple modes of modification. Trends Endocrinol Metab 2002, 13:55-60.
93. Halachmi S, Marden E, Martin G, et al. Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. Science 1994, 264:1455-1458.
94. Onate SA, Tsai SY, Tsai MJ, et al. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1996, 270:1354-1357.
95. Li H, Chen JD The receptor-associated coactivator 3 activates transcription through CREB-binding protein recruitment and autoregulation. J Biol Chem 1998, 273:5948-5954.
96. Lee SK, Kim HJ, Na SY, et al. Steroid receptor coactivator-1 coactivates activating protein-1-mediated transactivations through interaction with the c-Jun and c-Fos subunits. J Biol Chem 1998, 273:16651-16654.
97. Na SY, Lee SK, Han SJ, et al. Steroid receptor coactivator-1 interacts with the p50 subunit and coactivates NF-kB-mediated transactivation. J Biol Chem 1998, 273:10831-10834.
98. Onate SA, Boonyaratanakornkit V, Spencer TE, et al. The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF-1) and AF-2 domains of steroid receptors. J Biol Chem 1998, 273:12101-12108.
99. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev 1999, 9:40-48.
100. Yang XJ, Ogryzko VV, Nishikawa J, et al. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 1996, 382:319-324.
101. Voegel JJ, Heine MJ, Zechel C, et al. TIF2, a 160-kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J 1996, 15:3667-3675.
102. Hong H, Kohli K, Trivedi A, et al. GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. Proc Natl Acad Sci U S A 1996, 93:4948-4952.
103. Hong H, Kohli K, Garabedian MJ, et al. GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors. Mol Cell Biol 1997, 17:2735-2744.
104. Rogatsky I, Zarember KA, Yamamoto KR Factor recruitment and TIF2/GRIP1 corepressor activity at a collagenase-3 response element that mediates regulation by phorbol esters and hormones. EMBO J 2001, 20:6071-6083.
105. Anzick SL, Kononen J, Walker RL, et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997, 277:965-968.
106. Suen CS, Berrodin TJ, Mastroeni R, et al. A transcriptional coactivator, steroid receptor coactivqator-3, selectively augments steroid receptor transcriptional activity. J Biol Chem 1998, 273:27645-27653.
107. Wu RC, Qin J, Hashimoto Y, et al. Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) coactivator activity by IkB kinase. Mol Cell Biol 2002, 22:3549-3561.
108. Hankinson O The aryl hydrocarbon receptor complex. Ann Rev Pharmacol Toxicol 1995, 35:307-340.
109. McKenna NJ, Nawaz Z, Tsai SY, et al. Distinct steady-state nuclear receptor coregulator complexes exist in vivo. Proc Natl Acad Sci U S A 1998, 95:11697-11702.
110. Chrivia JC, Kwok RSP, Lamb N, et al. Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 1993, 365:855-859.
111. Kwok RSP, Lundblad JR, Chrivia JC, et al. Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature 1994, 370:223-226.
112. Kamei Y, Xu L, Heinzel T, et al. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 1996, 85:403-414.
113. Chakravarti D, LaMorte VJ, Nelson MC, et al. Role of CBP/p300 in nuclear receptor signalling. Nature 1996, 383:99-103.
114. Torchia J, Rose DW, Inostroza J, et al. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 1997, 387:677-684.
115. Yao TP, Ku G, Zhou N, et al. The nuclear hormone receptor coactivator SRC-1 is a specific target of p300. Proc Natl Acad Sci U S A 1996, 93:10626-10631.
116. Hanstein B, Eckner R, DiRenzo J, et al. p300 is a component of an estrogen receptor coactivator complex. Proc Natl Acad Sci U S A 1996, 93:11540-11545.
117. Kraus WL, Kadonaga JT p300 and estrogen receptor cooperatively activate transcription via differential enhancement of initiation and reinitiation. Genes Dev 1998, 12:331-342.
118. Hudson LG, Santon JB, Glass CK, et al. Ligand-activated thyroid hormone and retinoic acid receptors inhibit growth factor receptor promoter expression. Cell 1990, 62:1165-1175.
119. Glass CK, Rosenfeld MG The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 2000, 14:121-141.
120. Forman BM, Samuels HH Dimerization among nuclear hormone receptors. New Biol 1990, 2:587-594.
121. Baniahmad A, Ha I, Reinberg D, et al. Interaction of human thyroid hormone receptor beta with transcription factor TFIIB may mediate target gene derepression and activation by thyroid hormone. Proc Natl Acad Sci U S A 1993, 90:8832-8836.
122. Jonat C, Rahmsdorf HJ, Park KK, et al. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell 1990, 62:1189-1204.
123. Smith CL, Nawaz Z, O'Malley BW Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 1998, 11:657-666.
124. Montano MM, Ekena K, Delage-Mourroux R, et al. An estrogen receptorselective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. Proc Natl Acad Sci U S A 1999, 96:6947-6952.
125. Seol W, Choi HS, Moore DD An orphan nuclear hormone receptor that lacks a DNA binding domain and heterodimerizes with other receptors. Science 1996, 272:1336-1339.
126. Seol W, Hanstein B, Brown M, et al. Inhibition of estrogen receptor action by the orphan receptor SHP (short heterodimer partner). Mol Endocrinol 1998, 12:1551-1557.
127. Johansson L, Thomsen JS, Damdimopoulos AE, et al. The orphan nuclear receptor SHP inhibits agonist-dependent transcriptional activity of estrogen receptors ERα and ERβ. J Biol Chem 2002, 274:345-353.
128. Johansson L, Bavner A, Thomsen JS, et al. The orphan nuclear receptor SHP utilizes conserved LXXLL-related motifs for interactions with ligand-activated estrogen receptors. Mol Cell Bioll 2000, 20:1124-1133.
129. Korzus E, Torchia J, Rose DW, et al. Transcription factor-specific requirements for coactivators and their acetyltransferase functions. Science 1998, 279:703-707.
130. Nagy L, Kao HY, Chakravarti D, et al. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 1997, 89:373-380.
131. Knoepfler PS, Eisenman RN Sin meets NuRD and other tails of repression. Cell 1999, 99:447-450.
132. Arnold SF, Vorojeikina DP, Notides AC Phosphorylation of tyrosine 537 on the human estrogen receptor is required for binding to an estrogen response element. J Biol Chem 1995, 270:30205-30212.
133. Zhang QX, Borg A, Wolf DM, et al. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res 1997, 57:1244-1249.
134. Ali S, Metzger D, Bornert JM, et al. Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. EMBO J 1993, 12:1153-1160.
135. Arnold SF, Obourn JD, Jaffe H, et al. Phosphorylation of the human estrogen receptor by nitogen-activated protein kinase and casein kinase II: Consequence on DNA binding. J Steroid Biochem Mol Biol 1995, 55:163-172.
136. Kato S, Endoh H, Masuhiro Y, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995, 270:1491-1494.
137. Bunone G, Briand PA, Miksicek RJ, et al. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 1996, 15:2174-2183.
138. Aronica SM, Katzenellenbogen BS Stimulation of estrogen receptor-mediated transcription and alteration in the phosphorylation state of the rat uterine estrogen receptor by estrogen, cyclic adenosine monophosphate, and insulin-like growth factor-1. Mol Endocrinol 1993, 7:743-752.
139. Joel PB, Traish AM, Lannigan DA Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogenactivated protein kinase. J Biol Chem 1998, 273:13317-13323.
140. Chen DS, Pace PE, Coombes RC, et al. Phosphorylation of human estrogen receptor α by protein kinase A regulates dimerization. Mol Cell Biol 1999, 19:1002-1015.
141. Amold SF, Obourn JD, Jaffe H, et al. Serine 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor. Mol Endocrinol 1994, 8:1208-1214.
142. Joel PB, Smith J, Sturgill TW, et al. pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol Cell Biol 1998, 18:1978-1984.
143. Tremblay A, Tremblay GB, Labrie F, et al. Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. Mol Cell 1999, 3:513-519.
144. Ko L, Cardona GR, Iwasaki T, et al. Ser-884 adjacent to the LXXLL motif of coactivator TRBP defines selectivity for ERs and TRs. Mol Endocrinol 2002, 16:128-140.
145. Weigel NL, Zhang Y Ligand-independent activation of steroid hormone receptors. J Mol Med 1998, 76:469-479.
146. Hu E, Kim JB, Sarrf P, et al. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARγ. Science 1996, 274:2100-2103.
147. Taneja R, Rochette-Egly C, Plassat JL, et al. Phosphorylation of activation functions AF-1 and AF-2 of RARα and RARγ is indispensable for differentiation of F9 cells upon retinoic acid and cAMP treatment. EMBO J 1997, 16:6452-6465.
148. Shao D, Rangwata SM, Bailey ST, et al. Interdomain communication regulation ligand binding by PPAR-α. Nature 1998, 396:377-380.
149. Walker SE, Allen SH, McMurray RW Prolactin and autoimmune disease. Trends Endocrinol Metab 1993, 4:147-151.
150. Greenstein B, Roa R, Dhaher Y, et al. Estrogen and progesterone receptors in murine models of systemic lupus erythematosus. Int Immunopharmacol 2001, 1:1025-1035.
151. Wilson KB, Evans M, Abdou NI Presence of a variant form of the estrogen receptor in peripheral blood mononuclear cells from normal individuals and lupus patients. J Reprod Immunol 1996, 31:199-208.
152. Li H, Gomes PJ, Chen JD RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. Proc Natl Acad Sci U S A 1997, 94:8479-8484.
153. Chen H, Lin RJ, Schiltz RL, et al. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 1997, 90:569-580.
154. Takeshita A, Cardona GR, Koibuchi N, et al. TRAM-1, a novel 160-kDa thyroid hormone receptor activator molecule exhibits distinct properties from steroid receptor coactivator-1. J Biol Chem 1997, 272:27629-27634.